Emerging evidence on the pathobiology of mucositis

Simple item page
dc.contributor.authorAl-Dasooqi, N.
dc.contributor.authorSonis, S.
dc.contributor.authorBowen, J.
dc.contributor.authorBateman, E.
dc.contributor.authorBlijlevens, N.
dc.contributor.authorGibson, R.
dc.contributor.authorLogan, R.
dc.contributor.authorNair, R.
dc.contributor.authorStringer, A.
dc.contributor.authorYazbeck, R.
dc.contributor.authorElad, S.
dc.contributor.authorLalla, R.
dc.date.issued2013
dc.descriptionAn earlier version of this article was published in Volume 21, Issue 7, under DOI 10.​1007/​s00520-013-1810-y
dc.description.abstractBACKGROUND: Considerable progress has been made in our understanding of the biological basis for cancer therapy-induced mucosal barrier injury (mucositis). The last formal review of the subject by MASCC/ISOO was published in 2007; consequently, an update is timely. METHODS: Panel members reviewed the biomedical literature on mucositis pathobiology published between January 2005 and December 2011. RESULTS: Recent research has provided data on the contribution of tissue structure changes, inflammation and microbiome changes to the development of mucositis. Additional research has focused on targeted therapy-induced toxicity, toxicity clustering and the investigation of genetic polymorphisms in toxicity prediction. This review paper summarizes the recent evidence on these aspects of mucositis pathobiology. CONCLUSION: The ultimate goal of mucositis researchers is to identify the most appropriate targets for therapeutic interventions and to be able to predict toxicity risk and personalize interventions to genetically suitable patients. Continuing research efforts are needed to further our understanding of mucositis pathobiology and the pharmacogenomics of toxicity.
dc.description.statementofresponsibilityNoor Al-Dasooqi, Stephen T. Sonis, Joanne M. Bowen, Emma Bateman, Nicole Blijlevens, Rachel J. Gibson, Richard M. Logan, Raj G. Nair, Andrea M. Stringer, Roger Yazbeck, Sharon Elad, Rajesh V. Lalla, For The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer, International Society of Oral Oncology (MASCC, ISOO)
dc.identifier.citationSupportive Care in Cancer, 2013; 21(11):3233-3241
dc.identifier.doi10.1007/s00520-013-1900-x
dc.identifier.issn0941-4355
dc.identifier.issn1433-7339
dc.identifier.orcidBowen, J. [0000-0003-0876-0031]
dc.identifier.orcidBateman, E. [0000-0003-1665-102X]
dc.identifier.orcidGibson, R. [0000-0002-4796-1621]
dc.identifier.orcidLogan, R. [0000-0002-9331-1814]
dc.identifier.orcidStringer, A. [0000-0003-3245-5360]
dc.identifier.urihttp://hdl.handle.net/2440/93003
dc.language.isoen
dc.publisherSpringer-Verlag
dc.rights© Springer-Verlag Berlin Heidelberg 2013
dc.source.urihttps://doi.org/10.1007/s00520-013-1900-x
dc.subjectMucosal injury; Cancer therapy; Targeted drugs; Toxicity; Alimentary tract; Pharmacogenetics
dc.titleEmerging evidence on the pathobiology of mucositis
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Physiology publications